Acetazolamide as Additional Therapy in Patients with Decompensated Heart Failure Download PDF

A functional limitation and the need for prompt intervention come from the heart's inability to eject or accommodate blood within acceptable physiological pressure ranges, known as decompensated heart failure (DHF). It has undeniable epidemiological significance and clinical features. In AHF patients at high risk of diuretic resistance, the administration of acetazolamide enhances the natriuretic response to loop diuretics compared to an increase in loop diuretic dose. Decompensated heart failure (DHF) is a clinical syndrome characterized by the heart's not being able to eject and/or accommodate blood within accepted physiological pressure parameters, resulting in a functional limitation and the need for immediate intervention. It has undeniable epidemiological significance, as well as clinical features that have a direct impact on treatment. In AHF patients at high risk of diuretic resistance, the administration of acetazolamide enhances the natriuretic response to loop diuretics compared to an increase in loop diuretic dose. Acetazolamide improves diuretic efficacy, especially in cases of diuretic resistance. However, the balance between the possible advantages and risks must be carefully considered. The decision to include acetazolamide in the treatment plan should be guided by individual patient features such as renal function and comorbidities. The Medline, Pubmed, Embase, NCBI, and Cochrane databases were searched. Incidence, etiology, and management options were analyzed. Acetazolamide improves diuretic efficacy, especially in cases of diuretic resistance. However, the balance between the possible advantages and risks must be carefully considered. The decision to include acetazolamide in the treatment plan should be guided by individual patient features such as renal function and comorbidities.